CytRx tumbles after pricing stock offering

CytRx (CYTR -11.7%) has priced an 11.5M-share stock offering at $6.50, 19% below yesterday's closing price of $7.98. Underwriters have a 1.725M-share overallotment option. (PR)

Gross proceeds are set to total $75M. CytRx says it will use net proceeds to fund clinical trials for its Aldoxorubicin cancer drug, and for "general corporate purposes."

From other sites
Comments (1)
  • eigres
    , contributor
    Comments (21) | Send Message
    Seems like management cashed out... See latest article on pump and dump accusations dated 13 March 2014 Richard Pearson MoxReports
    13 Mar 2014, 05:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs